Have Therapeutics Enhanced Our Knowledge of Axial Spondyloarthritis?

McAllister K, Goodson N, Warburton L, Rogers G. Spondyloarthritis: diagnosis and management: summary of NICE guidance. Br Med J. 2017;356:j839.

Article  Google Scholar 

Khmenlinskii N, Regel A, Baraliakos X. The role of imaging in diagnosing axial spondyloarthritis. Front Med. 2018;5:106.

Article  Google Scholar 

Rudwaleit M, van der Heijde D, Landewé R, Akkoc N, Brandt J, Chou CT, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70(1):25–31.

Article  CAS  Google Scholar 

van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):987–91.

Google Scholar 

Baraliakos X, Kiltz U, Peters S, Appel H, Dybowski F, Igelmann M, et al. Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis. Rheumatol. 2017;56(1):95–102.

Article  CAS  Google Scholar 

Baraliakos X, Kiltz U, Peters S, Appel H, Dybowski F, Igelmann M, et al. Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis. Rheumatol. 2017;56(1):95–102.

Article  CAS  Google Scholar 

Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002;346(18):1349–56.

Article  CAS  Google Scholar 

National Institute of Clinical Excellence. TNF-inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis [Internet]. London.  2016 [cited 2021 May 1]. Available from: https://www.nice.org.uk/guidance/ta383/resources/tnfalpha-inhibitors-for-ankylosing-spondylitis-and-nonradiographic-axial-spondyloarthritis-pdf-2984675907013

National Institute of Clinical Excellence (NICE). Secukinumab for treating non-radiographic axial spondyloarthritis [TA719] [Internet]. London. 2021 [cited 2022 Aug 10]. Available from: https://www.nice.org.uk/guidance/ta719

National Institute of Clinical Excellence (NICE). Ixekizumab for treating axial spondyloarthritis [TA718] [Internet]. London. 2021 [cited 2022 Aug 10]. Available from: https://www.nice.org.uk/guidance/ta718

National Institute of Clinical Excellence (NICE). Upadacitinib for treating active ankylosing spondylitis [ID3848] [Internet]. London. 2022 [cited 2022 Aug 10]. Available from: https://www.nice.org.uk/guidance/indevelopment/gid-ta10735

National Institute of Clinical Excellence (NICE). Tofacitinib for treating active ankylosing spondylitis [ID3865] [Internet]. London. 2022 [cited 2022 Aug 10]. Available from: https://www.nice.org.uk/guidance/indevelopment/gid-ta10771

Braun J, Brandt J, Listings J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002;359(9313):1187–93.

Article  CAS  Google Scholar 

Wei JC, Kim T, Kishimoto M, Ogusu N, Jeong H, Kobayashi S, et al. Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial. Ann Rheum Dis. 2021;80(8):1014–21.

Article  Google Scholar 

UCB Biopharma SRL. A study to evaluate the efficacy and safety of bimekizumab in subjects with active nonradiographic axial spondyloarthritis (BE MOBILE 1) [Internet]. Bethsada. 2019 [cited 2022 Aug 10]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03928704

UCB Biopharma SRL. A study to evaluate the efficacy and safety of bimekizumab in subjects with active ankylosing spondylitis (BE MOBILE 2) [Internet]. Bethsada. 2019 [cited 2022 Aug 10]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03928743

van der Heijde D, Genslet LS, Doedhar A, Baraliakos X, Poddubnyy D, Kivitz A, et al. Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2020;79(5):595–604.

Article  Google Scholar 

UCB Biopharma S.P.R.L. A study to evaluate the long-term safety, tolerability and efficacy of bimekizumab in subjects with active axial spondyloarthritis including ankylosing spondylitis and nonradiographic axial spondyloarthritis (BE MOVING) [Internet]. Bethesda. 2020 [cited 2021 Apr 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT04436640

Izana Bioscience Ltd. Efficacy and safety of namilumab for moderate-to-severe axial spondyloarthritis (NAMASTE) [Internet]. Bethsada. 2022 [cited 2022 Aug 10]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT03622658

van der Heijde D, Baraliakos X, Gensler LS, Maksyowych WP, Tseluyko V, Nadashkevich O, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10162):2378–87.

Article  Google Scholar 

Deodhar A, Gensler LS, Sieper J, Clark M, Calderon C, Wang Y, et al. Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis. Arthritis Rheumatol. 2019;71(2):258–70.

Article  CAS  Google Scholar 

Baeten D, Østergaard M, Wei JC, Sieper J, Järvinen P, Tan L, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis. 2018;77(9):1295–302.

Article  CAS  Google Scholar 

Mease PJ, Chohan S, Fructuoso FJG, Luggen ME, Rahman P, Raychaudhuri SP, et al. Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study. Ann Rheum Dis. 2021;80(9):1147–57.

Article  CAS  Google Scholar 

Poddubnyy D, Hermann KA, Callhoff J, Listings J, Sieper J. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis. 2014;73(5):817–23.

Article  CAS  Google Scholar 

Braun J, Bollow M, Eggens U, König H, Distler A, Sieper J. Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis rheum. 1994;37(7):1039–45.

Article  CAS  Google Scholar 

Bal A, Unlu E, Bahar G, Aydog E, Elsioglu E, Yorgancioglu R. Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol. 2007;26(2):211–5.

Article  CAS  Google Scholar 

Liu W, Wu Y, Zhang L, Xue B, Wang YBL, et al. Elevated serum levels of IL-6 and IL-17 may associate with the development of ankylosing spondylitis. Int J Clin Exp Med. 2015;8(10):17362–76.

Google Scholar 

Pedersen SJ, Hetland ML, Sørensen IJ, Ostergaard M, Nielsen HJ, Johansen JS. Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFα inhibitors. Clin Rheumatol. 2010;29(11):1301–9.

Article  Google Scholar 

Tan AL, Marzo-Ortega H, O’Connor P, Fraser A, Emery P, McGonagle D. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis. 2004;63(9):1041–5.

Article  CAS  Google Scholar 

Haibel H, Rudwaleit M, Listing J, Sieper J. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis. 2005;64(2):296–8.

Article  CAS  Google Scholar 

Sieper J, Braun J, Kay J, Badalamenti S, Radin AR, Jiao L, et al. Sarilumab for the treatment of ankylosing spondylitis: results of a phase II, randomised, double-blind, placebo-controlled study (ALIGN). Ann Rheum Dis. 2015;74(6):1051–7.

Article  CAS  Google Scholar 

Sieper J, Porter-Brown B, Thompson L, Harari O, Dougados M. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis. 2014;73:1051–7.

Article  Google Scholar 

Meralshi M, De Marco G, Podgorski M, McGonagle D, Marzo-Ortega H. Evidence of response to IL-6 inhibition in some cases of refractory spondyloarthritis-associated peripheral synovitis. Ann Rheum Dis. 2016;75(7):209275.

Google Scholar 

Baeten DL, Kuchroo VK. How Cytokine Networks Fuel Inflammation: Interleukin-17 and a tale of two autoimmune diseases. Nat Med. 2013;19:824–5.

Article  CAS  Google Scholar 

Marzo-Ortega H. Axial spondyloarthritis: coming of age. Rheumatol. 2020;59(suppl4):iv1-5.

Article  Google Scholar 

Brown MA, Li Z, Cao KL. Biomarker development for axial spondyloarthritis. Nat Rev Rheumatol. 2020;16(8):448–63.

Article  Google Scholar 

Gracey E, Vereecke L, McGovern D, Frohling M, Schett G, Danese S, et al. Revisiting the gut–joint axis: links between gut inflammation and spondyloarthritis. Nat Rev Rheumatol. 2020;16:415–33.

Article  Google Scholar 

Gracey E, Burssens A, Cambre I, Scheet G, Lories R, McInnes IB, et al. Tendon and ligament mehanical loading in the pathogenesis of inflammatory arthritis. Nat Rev Rheumatol. 2020;16:193–207.

Article  Google Scholar 

Holbrook J, Lara-Reyna S, Jarosz-Griffiths H, McDermott M. Tumour necrosis factor signalling in health and disease. F1000Res. 2019;8:111.

Article  CAS  Google Scholar 

Garriets V, Goyal A, Khaddour K. Tumour Necrosis Factor Inhibitors. Florida: StatPearls Publishing; 2021. p. 1–14.

Google Scholar 

Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Parmacology Ther. 2008;117(2):244–79.

Article  CAS  Google Scholar 

Menegatti S, Guillemot V, Latis E, Yahia-Cherbal H, Mittermüller D, Rouilly V, et al. Immune response profiling of patients with spondyloarthritis reveals signalling networks mediating TNF-blocker function in vivo. Ann Rheum Dis. 2021;80(4):475–86.

Article  CAS  Google Scholar 

Bautista-Caro M, Arroyo-Villa I, Castillo-Gallego C, Miguel E, Peiteado D, Puig-Kröger A, et al. Decreased Th17 and Th1 cells in the peripheral blood of patients with early non-radiographic axial spondyloarthritis: a marker of disease activity in HLA-B27+ patients. Rheumatol (Oxford). 2013;52(2):352–62.

Article  CAS  Google Scholar 

Garcia-Montoya L, Emery P. Disease modification in ankylosing spondylitis with TNF inhibitors: spotlight on early phase clinical trials. Expert Opin Investig Drugs. 2021;30(11):1109–24.

Article  CAS  Google Scholar 

Lata M, Hettinghouse AS, Liu C. Targeting tumor necrosis factor receptors in ankylosing spondylitis. Ann N Y Acad Sci. 2019;1442(1):5–16.

Article  Google Scholar 

Kishimoto M, Ono K, Fukui S, Kawaai S, Deshpande GA, Yoshida K, et al. Clinical characteristics of non-radiographic versus radiographic axial spondyloarthritis in Asia and non-radiographic axial spondyloarthritis in other regions: results of the cross-sectional ASAS-COMOSPA study. RMD Open. 2021;7(3):e001752.

Article  Google Scholar 

Onna MV, Jurik AG, van der Heijde D, van Tubergen A, Heuft-Dorenbosch L, Landewé R. HLA-B27 and gender independently determine the likelihood of a positive MRI of the sacroiliac joints in patients with early inflammatory back pain: a 2-year MRI follow-up study. Ann Rheum Dis. 2011;70(11):1981–5.

Article  Google Scholar 

Wong-Baeza I, Rodley A, Shaw J, Hatano H, Rysnik O, McHugh K, et al. KIR3DL2 binds to HLA-B27 dimers and free H chains more strongly than other HLA class I and promotes the expansion of T cells in ankylosing spondylitis. J Immunol. 2013;190(7):3216–24.

Article  CAS  Google Scholar 

Bowness P, Ridley A, Shaw J, Chan AT, Wong-Baeza I, Fleming M, et al. Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis. J Immunol. 2011;186(4):2672–80.

Article  CAS  Google Scholar 

Gravallese EM, Schett G. Effects of the IL-23–IL-17 pathway on bone in spondyloarthritis. Nat Rev Rheumatol. 2018;1

留言 (0)

沒有登入
gif